DUBLIN and PERTH, Australia – Sensorion SA is teaming up with Cochlear Ltd. to explore the potential for combining drug therapy with cochlear implant surgery to improve patient outcomes.
DUBLIN and PERTH, Australia – Sensorion SA is teaming up with Cochlear Ltd. to explore the potential for combining drug therapy with cochlear implant surgery to improve patient outcomes. The two companies will spend next year evaluating Sensorion's clinical-stage drug candidate, SENS-401, with Cochlear's implantable devices in a number of preclinical models. If that work is successful, clinical trials could follow in 2019.
PERTH, Australia – Investment in research and development fell sharply in the last decade in Australia, and the government can play an important role to improve framework conditions that support innovation, according to the Australian Innovation System Report 2017.
PERTH, Australia – Belgium's Tigenix NV licensed intellectual property from Australian stem cell company Mesoblast Ltd. the same day it announced approval of the EU's first allogeneic stem cell therapy. The deal supported Tigenix's global commercialization of the adipose-derived mesenchymal stem cell product, Cx601, for the local treatment of fistulae for Crohn's disease. (See BioWorld, Dec. 18, 2017.)
PERTH, Australia – Belgium’s Tigenix NV licensed intellectual property from Australian stem cell company Mesoblast Ltd. the same day it announced approval of the EU’s first allogeneic stem cell therapy.
PERTH, Australia – Investment in research and development fell sharply in the last decade in Australia, and the government can play an important role to improve framework conditions that support innovation, according to the Australian Innovation System Report 2017.
PERTH, Australia – IP Australia released its final recommendations on five separate intellectual property policy amendments put forward by the Productivity Commission that are expected to make their way through Parliament in 2018.
